Dr. Gopal R. Kunta, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 642
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME91372
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Orlando Orlando, FL
- Orlando Health Orlando, FL
- Orlando Health South Lake Hospital Clermont, FL
Medical groups
- Clermont Oncology Center LLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 642
- Services billed
- 439,427
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, iron sucrose, 1 mg | 222,902 | 170 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 14,261 | 38 |
| Injection, denosumab, 1 mg | 10,860 | 55 |
| Injection, ondansetron hydrochloride, per 1 mg | 6,464 | 43 |
| Injection, dexamethasone sodium phosphate, 1 mg | 5,312 | 87 |
| Insertion of needle into vein for collection of blood sample | 2,332 | 553 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 2,287 | 535 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,503 | 539 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 1,274 | 205 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 1,056 | 145 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Clermont, FL | 187 |
| Prednisone Other prescribers in Clermont, FL | 162 |
| Abiraterone Acetate | 142 |
| Eliquis (apixaban) Other prescribers in Clermont, FL | 108 |
| Anastrozole Other prescribers in Clermont, FL | 100 |
| Zoledronic Acid | 99 |
| Dexamethasone Other prescribers in Clermont, FL | 96 |
| Retacrit (epoetin alfa-epbx) | 95 |
| Ondansetron Hcl Other prescribers in Clermont, FL | 93 |
| Lupron Depot (leuprolide acetate) | 91 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 41 companies reported 96 payments worth $3,453 in total to this clinician.
| Merck Sharp & Dohme LLC | $754 |
|---|---|
| Beone Medicines USA, Inc. | $210 |
| Novartis Pharmaceuticals Corporation | $190 |
| AbbVie Inc. | $176 |
| Asd Specialty Healthcare, LLC | $174 |
| Gilead Sciences, Inc. | $151 |
| Stemline Therapeutics Inc. | $143 |
| AstraZeneca Pharmaceuticals LP | $142 |
| Food and Beverage | $2,827 |
|---|---|
| Consulting Fee | $530 |
| Education | $95.95 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Oct 10, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a research engagement. | $530 |
| Seagen Inc. Aug 25, 2025 | Education in-kind | $95.95 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 6 companies. The companies reported $646,271 in research payments for these studies, mostly to the institutions running them.
- CGME751A12101
Hexal AG - A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05785767 - A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06161441 - Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Sanofi US Services Inc. · Terminated · NCT04717375 - An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
Merck Sharp & Dohme LLC - A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A Versus Intravenous Pembrolizumab, Administered With Ch…
Merck Sharp & Dohme LLC - KEYMAKER-U01 Substudy 01J# A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NS…
Merck Sharp & Dohme LLC - BNT327
BioNTech SE - KEYMAKER-U01 Substudy 01F# A Phase 1b,2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC With KRAS…
Merck Sharp & Dohme LLC - ALI-4201
Puma Biotechnology, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.